Fully Enrolled Confirmatory Studies Can De-Risk Novel Accelerated Approval Endpoints – FDA Official

 
• By Sarah Karlin-Smith
  
pencil erasing word risk
Novel cancer endpoints may get more regulatory leeway in context of Project Frontrunner • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D